Exercise Rehabilitation for Patients With Critical Limb Ischemia After Revascularization

May 23, 2019 updated by: Randy Moore, University of Calgary

Exercise Rehabilitation for Critical Limb Ischemia Patients After Revascularization: Pilot Randomized Controlled Trial Assessing Functional Capacity and Quality of Life After a 12-week Rehabilitation Program Versus Best Medical Therapy

Peripheral arterial disease (PAD) affects more than 200 million people worldwide. This disease occurs with narrowing and occlusion of arteries supplying oxygenated blood to the organs and limbs. Symptomatic patients typically experience leg pain with physical activity. More advanced disease states are referred to as critical limb ischemia (CLI), where patients may have leg pain at rest or non-healing wounds. Primary treatment of PAD involves risk factor management; smoking cessation, management of blood pressure, blood cholesterol, diabetes, and exercise prescription. Patients with CLI typically require interventions to reestablish blood supply to their limbs. There is currently minimal understanding of the role for exercise rehabilitation after revascularization procedures in this vulnerable population. This is the first clinical to understand the role of exercise for these patients. We hypothesize that exercise rehabilitation after revascularization will improve quality of life and functional capacity in these patients.

Study Overview

Detailed Description

Background: Peripheral arterial disease (PAD) refers to narrowing and occlusion of arteries supplying oxygenated blood to non-coronary and non-intracranial circulatory systems. This term is typically used to describe disease in the legs though it also affects upper extremities, renal and mesenteric vessels. Symptomatic patients typically experience leg pain with walking or physical activity which is referred to as intermittent claudication (IC). In more advanced chronic disease states with severely compromised blood flow to the tissues, patients may have leg pain at rest or even non healing wounds that can lead to tissue loss which is defined as critical limb ischemia (CLI).

Risk factor management is critical for PAD patients with the goal of improving symptoms and preventing disease progression. This includes smoking cessation as well as appropriate management for hypertension, dyslipidemia and diabetes. Antiplatelet therapy should be initiated in symptomatic patient or when other risk factors are present. Exercise interventions should be encouraged in all patients with PAD. In patients who have progressed to critical limb ischemia, treatment goals are to relieve pain, heal wounds and prevent limb loss. In addition to risk factor management and medical therapy, these patients require revascularization procedures. Depending on the extent and location of disease, the techniques used may be endovascular/interventional (minimally invasive), surgical, or a hybrid combination of the two.

There has been minimal research examining exercise rehabilitation after revascularization. There are no studies that have focused on exercise rehabilitation exclusively in patients with CLI.

Purpose/Objectives: The aim of this study is to develop a better understanding of the role for supervised exercise rehabilitation programs (SEP) in PAD-CLI patients after revascularization. This pilot study will assess the feasibility for expanding this research to a larger randomized controlled trial.

Study Design:

This is a two-phase, single-center, non-blinded randomized controlled trial.

Objectives:

In phase 1, the investigators will assess feasibility. Specifically, the investigators will assess rate of enrollment, barriers to participation and any methodological challenges that may require changes. If phase 1 of this study shows reasonable rates of enrollment and no methodological challenges, we will proceed to phase 2.

Key objectives for phase 2 are as follows:

  1. The primary objective is to show how SEP affects functional capacity and quality of life in patients with PAD-CLI after revascularization.
  2. The secondary objective is to show how SEP affects the rate of major adverse limb events (MALE) and improve survival in patients with PAD-CLI after revascularization.

Hypotheses: 1) PAD-CLI patients who have undergone revascularization will have a greater improvement in functional capacity and quality of life compared with patients treated with best medical therapy alone.

2) PAD-CLI patients who have undergone revascularization will have fewer MALE and improved survival compared with patients treated with best medical therapy alone.

Methodology: Patients included in the study will be identified in the vascular surgery outpatient clinic or through emergency department as requiring revascularization secondary to critical limb ischemia. Patients will be approached regarding study participation prior to the revascularization procedure. After eligibility is confirmed and patients have signed informed consent, patients will be randomized to one of two groups:

  1. Best Medical Therapy (BMT): Appropriate risk factor management, encouragement to mobilize.
  2. Supervised Exercise Program (SEP): consist of BMT plus a supervised exercise program.

Patients will undergo evaluation of functional capacity assessment using a graded treadmill test at the outset of the study and after 12 weeks of either BMP or SEP. The investigators will also administer a validated quality of life (QoL) questionnaire to the two different groups at the outset and completion of the study. Patients will be followed annually to monitor for MALE and survival.

Statistics: Normally distributed data will be presented as mean ± SD. Results at baseline and 12 weeks will be compared using a paired t-test. For data that is not normally distributed, comparisons will be performed using a non-parametric Mann-Whitney test. Comparisons will be accepted as statistically significant at 95% confidence level (p≤0.05). STATA software will be used for statistical analysis.

Study Type

Interventional

Enrollment (Anticipated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T1Y 6J4
        • Peter Lougheed Center, Alberta Health Services, University of Calgary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Ambulating prior to procedure
  2. Living independently prior to procedure
  3. Available to attend all SEP and follow-up appointments
  4. PAD Fontaine class III and IV (rest pain and tissue loss)
  5. Entry with consent of vascular surgeon
  6. Ischemia secondary to TASC A-D lesions identified on imaging (CTA or angiogram)
  7. Able to understand and sign informed consent
  8. >18 years of age

Exclusion Criteria:

  1. Confined to wheelchair
  2. Patients with exercise tolerance limitations due to other co-morbidities such as cardiorespiratory, musculoskeletal, or peripheral neuropathy. (NYHA class III and IV)
  3. PAD Fontaine class I and II (asymptomatic, claudication)
  4. Patients with ongoing tissue loss that limits ambulation
  5. Patient with previous revascularization procedures
  6. Patients undergoing revascularization for acute limb ischemia events

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Best Medical Therapy
After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
Experimental: Supervised Exercise Program
Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of enrollment
Time Frame: 3 months
A minimum of 3 patients per month should be enrolled
3 months
Functional Capacity
Time Frame: Three months
Functional capacity will be evaluated by a six-minute walk test
Three months
Quality of Life assessed by VascuQuol questionnaire
Time Frame: Three months
Questionnaire with 25 items validated for patients with peripheral arterial disease
Three months
Health status assess by SF-36
Time Frame: Three months
36-item self-reported survey that provides a measure of patient health
Three months
Barriers or experiences with physical activity
Time Frame: Three months
We will conduct a 30-minute interview to gain better understanding of patient experiences with exercise rehabilitation.
Three months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major adverse limb events (MALE)
Time Frame: Five years
Clinical deterioration or condition requiring surgical interventions
Five years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Randy D Moore, MD, University of Calgary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2019

Primary Completion (Anticipated)

January 1, 2020

Study Completion (Anticipated)

July 1, 2020

Study Registration Dates

First Submitted

February 4, 2019

First Submitted That Met QC Criteria

February 11, 2019

First Posted (Actual)

February 15, 2019

Study Record Updates

Last Update Posted (Actual)

May 28, 2019

Last Update Submitted That Met QC Criteria

May 23, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on Best Medical Therapy

Subscribe